These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20407451)

  • 41. SmithKline's ulcer medicine "holy war".
    Dreyfuss J
    Fortune; 1983 Sep; 108(6):129-30, 134-6. PubMed ID: 10262256
    [No Abstract]   [Full Text] [Related]  

  • 42. Drug developer strategies to boost competitiveness.
    Belsey MJ
    Nat Rev Drug Discov; 2007 Apr; 6(4):265-6. PubMed ID: 17457999
    [No Abstract]   [Full Text] [Related]  

  • 43. Should platform companies move toward products?
    Ratner M
    Nat Biotechnol; 1999 Jan; 17(1):16-7. PubMed ID: 9920255
    [No Abstract]   [Full Text] [Related]  

  • 44. Global outsourcing.
    Garofolo W; Garofolo F
    Bioanalysis; 2010 Feb; 2(2):149-52. PubMed ID: 21083294
    [No Abstract]   [Full Text] [Related]  

  • 45. Competitive collaboration in the pharmaceutical and biotechnology industry.
    Bingham A; Ekins S
    Drug Discov Today; 2009 Dec; 14(23-24):1079-81. PubMed ID: 19835979
    [No Abstract]   [Full Text] [Related]  

  • 46. Strategic alliance management: lessons learned from the Bayer-Millennium collaboration.
    Ziegelbauer K; Farquhar R
    Drug Discov Today; 2004 Oct; 9(20):864-8. PubMed ID: 15475317
    [No Abstract]   [Full Text] [Related]  

  • 47. Impact of non-profit organizations on drug discovery: opportunities, gaps, solutions.
    Matter A; Keller TH
    Drug Discov Today; 2008 Apr; 13(7-8):347-52. PubMed ID: 18405848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Medical innovations in the age of diagnosis-related groups (DRGs)].
    Mäurer J
    Dtsch Med Wochenschr; 2007 Jan; 132(1-2):45. PubMed ID: 17187324
    [No Abstract]   [Full Text] [Related]  

  • 49. Chinese manufacturers vie for piece of outsourcing pie.
    Jia H
    Nat Biotechnol; 2007 Dec; 25(12):1337-8. PubMed ID: 18066012
    [No Abstract]   [Full Text] [Related]  

  • 50. India takes an open source approach to drug discovery.
    Singh S
    Cell; 2008 Apr; 133(2):201-3. PubMed ID: 18423188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Striking the right balance between innovation and drug price competition: putting the Hatch-Waxman Act into perspective.
    Deal JB
    Food Drug Law J; 1999; 54(2):185-6. PubMed ID: 11759712
    [No Abstract]   [Full Text] [Related]  

  • 52. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 53. Shaping the future of safer innovative drugs in Europe.
    Mestres J; Bryant SD; Zamora I; Gasteiger J
    Nat Biotechnol; 2011 Sep; 29(9):789-90. PubMed ID: 21904315
    [No Abstract]   [Full Text] [Related]  

  • 54. Is there a best strategy for drug discovery?
    Warne P; Page C
    Drug News Perspect; 2003 Apr; 16(3):177-82. PubMed ID: 12819816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 58. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 59. Can affordability and innovation coexist for medicines?
    Colbert A; Rintoul A; Simão M; Hill S; Swaminathan S
    BMJ; 2020 Jan; 368():l7058. PubMed ID: 31932276
    [No Abstract]   [Full Text] [Related]  

  • 60. Pharmaceutical downsizing and oncology drug development.
    Senior K
    Lancet Oncol; 2008 Jan; 9(1):11. PubMed ID: 18183658
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.